Home > Adults > Gynaecology >

Ovarian Conditions

Checked: 23-04-2017 by katy baetjer Next Review: 23-10-2017

Polycystic Ovary Syndrome (PCOS)

Please refer to the PCOS section of Remedy.

Premature Ovarian Failure

Please refer to the guidelines for the management of Premature Ovarian Failure (word doc) created by Dr Rachel Brown, Gynaecology GPSI (Montpelier Health Centre)

Ovarian Cyst

The Primary Care Ovarian Cyst pathway (PDF) has been compiled by Dr Tim Percival, Dr Nicola McGuinness (GP, The Family Practice), Phil Smith (Consultant Gynaecologist, North Bristol NHS Trust) and Caroline Overton (Consultant Gynaecologist, UHBristol).

CA125

Please see CKS advice regarding indication for a CA125 test and interpretation of results:

Managing a woman with suspected ovarian cancer - CKS (1)

CA125 can be used to investigate symptomatic patients where there are concerns that their symptoms could be caused by ovarian cancer, this includes patients with non-specific symptoms who are being investigated before referral on the Non- Specific Symptoms USC (2WW) pathway.

Please note that a raised CA125 alone is not an indication for an USC (2WW) referral. See the Gynaecology - USC (2WW) page for further details and indications for referral.This page also has a CA125 flow chart which may be helpful and also has advice on other causes of raised CA125 if ovarian cancer is excluded.

Patient Leaflet

What is a CA125 blood test? | Patient

Resources

(1) Managing a woman with suspected ovarian cancer - CKS

(2) CA-125 Blood Test: Results, Normal Range & What To Expect (clevelandclinic.org)

Efforts are made to ensure the accuracy and agreement of these guidelines, including any content uploaded, referred to or linked to from the system. However, BNSSG ICB cannot guarantee this. This guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer, in accordance with the mental capacity act, and informed by the summary of product characteristics of any drugs they are considering. Practitioners are required to perform their duties in accordance with the law and their regulators and nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.

Information provided through Remedy is continually updated so please be aware any printed copies may quickly become out of date.